Mounjaro & Ulcerative Colitis Timeline | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro UK Price - From £124.99

Get the cheapest UK price on Mounjaro from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

WEIGHTLOSSNEW £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro And Ulcerative Colitis Timeline: What Happens

Published on: June 03, 2026

Understanding the mounjaro and ulcerative colitis timeline UK is essential if you're considering tirzepatide treatment whilst managing inflammatory bowel disease. At Cured Pharmacy, our UK prescribers carefully assess each patient's medical history, including active or previous ulcerative colitis, before determining suitability for Mounjaro treatment from £124.99.

Understanding Mounjaro and Inflammatory Bowel Disease

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Whilst the SURPASS clinical trial programme demonstrated significant weight loss outcomes, patients with active inflammatory bowel disease including ulcerative colitis were generally excluded from these pivotal studies.

Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum, characterised by periods of flare and remission. The gastrointestinal side effects commonly associated with GLP-1 receptor agonists—including nausea, diarrhoea, and abdominal discomfort—may overlap with or potentially exacerbate ulcerative colitis symptoms [2]. This is why a thorough prescriber assessment is essential before starting treatment.

Current clinical guidance suggests that patients with well-controlled ulcerative colitis in remission may be considered for Mounjaro treatment, subject to individual prescriber assessment. However, those experiencing active flares, recent hospitalisations, or poorly controlled disease typically require stabilisation of their IBD before weight loss medication can be safely initiated.

Week-by-Week Timeline: What to Expect

The mounjaro and ulcerative colitis timeline UK follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects whilst your body adjusts to treatment. Understanding this progression helps you recognise normal adjustment symptoms versus potential IBD flare indicators.

During weeks 1-4, you'll start on the lowest maintenance dose of 2.5 mg once weekly. This initiation phase allows your digestive system to adapt gradually to tirzepatide's effects on gastric emptying and intestinal motility. Patients with ulcerative colitis should monitor bowel frequency, stool consistency, and any blood or mucus—symptoms that differ from typical GLP-1 side effects.

Weeks 5-8 typically involve dose escalation to 5 mg weekly, subject to tolerability and prescriber approval. At this stage, most patients experience peak gastrointestinal adjustment symptoms. Those with ulcerative colitis should maintain close communication with both their gastroenterologist and prescribing clinician, as distinguishing between medication-related diarrhoea and an IBD flare requires clinical expertise.

Months 2-6: Stabilisation and Monitoring

From week 9 onwards, doses may be increased incrementally to 7.5 mg, 10 mg, 12.5 mg, or the maximum 15 mg dose, depending on weight loss response and tolerability. Each increase occurs at four-week intervals minimum. For patients managing ulcerative colitis, this gradual approach is particularly important—rapid escalation could make it difficult to differentiate medication side effects from disease activity [3].

Throughout this period, your UK prescriber will assess whether gastrointestinal symptoms are stabilising or worsening. Persistent diarrhoea lasting beyond the typical 4-6 week adjustment window, the presence of blood in stools, or increasing abdominal pain warrant immediate medical review and may indicate the need to pause or discontinue treatment.

Key Safety Considerations for IBD Patients

Patients with ulcerative colitis considering Mounjaro must understand specific safety considerations that differ from the general population. The medication's mechanism—slowing gastric emptying and reducing appetite—can affect nutrient absorption and hydration status, both critical factors in IBD management [4].

Dehydration risk increases with GLP-1 receptor agonists due to reduced fluid intake from appetite suppression and potential diarrhoea. For ulcerative colitis patients already at risk during flares, maintaining adequate hydration becomes doubly important. Your prescriber will likely recommend specific fluid intake targets and electrolyte monitoring, particularly during dose escalation phases.

Medication interactions also require careful review. Many ulcerative colitis patients take immunosuppressants, biologics, or aminosalicylates. Whilst no direct pharmacokinetic interactions exist between tirzepatide and common IBD medications, the altered gastric emptying may affect absorption timing of oral IBD treatments. Your gastroenterologist should be informed before starting Mounjaro to optimise your entire medication schedule.

When Mounjaro May Not Be Suitable

Absolute contraindications for Mounjaro include personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. For ulcerative colitis patients specifically, active disease flares, recent bowel surgery, or a history of toxic megacolon represent relative contraindications requiring specialist gastroenterology input before treatment can be considered.

Patients who have experienced severe IBD complications, including perforation, strictures, or multiple hospitalisations in the past year, typically require alternative weight management approaches. Your Cured Pharmacy prescriber will review your complete medical history during the free online consultation to determine individual suitability.

Treatment Mechanism GI Side Effects Starting Price
Mounjaro (tirzepatide) Dual GIP/GLP-1 agonist Nausea, diarrhoea, reduced appetite From £124.99
Wegovy (semaglutide) GLP-1 agonist Nausea, diarrhoea, constipation From £69.00
Saxenda (liraglutide) GLP-1 agonist (daily) Nausea, diarrhoea, vomiting From £68.00
Orlistat Lipase inhibitor Oily stools, urgency, flatulence From £32.00
Mysimba Naltrexone/bupropion Nausea, constipation (less GI impact) From £125.95

Monitoring Your Symptoms: Red Flags vs Normal Side Effects

Distinguishing between expected Mounjaro side effects and ulcerative colitis flare symptoms is crucial for safe treatment. Normal GLP-1 side effects include mild to moderate nausea, occasional loose stools, reduced appetite, and transient abdominal discomfort that improves over 2-4 weeks [1]. These symptoms should gradually diminish, not intensify.

Red flag symptoms requiring immediate medical attention include bloody diarrhoea, severe abdominal cramping that worsens rather than improves, fever above 38°C, signs of dehydration (dark urine, dizziness, reduced urination), or more than six bowel movements daily. These may indicate an ulcerative colitis flare rather than medication adjustment and require urgent gastroenterology review.

Keep a detailed symptom diary during your first three months on Mounjaro, recording bowel frequency, stool consistency using the Bristol Stool Chart, any blood or mucus, pain severity, and associated symptoms. This documentation helps your prescriber and gastroenterologist make informed decisions about continuing, adjusting, or discontinuing treatment.

Alternative Weight Loss Options for Ulcerative Colitis Patients

If Mounjaro is deemed unsuitable due to active ulcerative colitis or previous intolerance to GLP-1 medications, several alternative weight loss treatments may be considered. Each option carries its own risk-benefit profile for IBD patients and requires individual prescriber assessment.

Orlistat-based treatments work through a different mechanism—blocking fat absorption in the intestine rather than affecting appetite hormones. Whilst this can cause loose, oily stools in all patients, those with ulcerative colitis may find these side effects particularly problematic during flares. However, for patients in stable remission, orlistat may represent a viable alternative with less impact on gastric emptying.

Mysimba (naltrexone/bupropion combination) acts centrally on appetite regulation without directly affecting gastrointestinal motility. This may suit some ulcerative colitis patients better, though the medication requires careful monitoring for mood changes and blood pressure. Your UK prescriber will discuss all licensed options during your consultation, tailoring recommendations to your specific IBD status and weight loss goals.

Non-Pharmacological Approaches

Some ulcerative colitis patients in active disease phases may benefit from focusing on dietary management and physical activity optimisation before introducing weight loss medications. Working with a dietitian experienced in both IBD and weight management can help identify trigger foods, ensure adequate nutrition during remission, and establish sustainable eating patterns that support both conditions.

Once your ulcerative colitis achieves stable remission—typically defined as consistent symptom control for at least three to six months—your gastroenterologist and prescriber can reassess suitability for pharmacological weight loss interventions including Mounjaro.

How Cured Pharmacy Supports Patients with Complex Medical Histories

At Cured Pharmacy, our UK-registered clinical team understands that patients with ulcerative colitis require more detailed assessment than standard weight loss consultations. Our online consultation process includes specific questions about IBD type, current disease activity, recent flares, current medications, and gastroenterology care arrangements.

Superintendent pharmacist Tarun Kumar (GPhC 2233073) and our prescribing team review each application individually, often requesting additional information from your gastroenterologist when appropriate. This collaborative approach ensures treatment decisions prioritise both safety and efficacy. We never rush complex cases—your consultation may take longer than the typical three minutes when additional medical history requires review.

If Mounjaro is prescribed, we provide detailed patient information specific to IBD management, including symptom monitoring guidance, when to contact your gastroenterologist, and how to recognise concerning changes. Our pharmacy team remains available throughout your treatment journey for questions about administration, side effects, or any concerns about your ulcerative colitis status. All consultations are conducted by UK-registered prescribers, and every medication dispensed is genuine and UK-licensed.

Starting Your Assessment

To begin your assessment for Mounjaro or alternative weight loss treatments, complete our free online consultation. Be thorough when describing your ulcerative colitis history—including diagnosis date, typical flare frequency, current medications, and most recent gastroenterology review. This information allows our prescribers to make informed, safe decisions about your treatment options.

If you're currently experiencing an ulcerative colitis flare or have had recent disease activity, our prescriber may recommend postponing weight loss medication until your IBD is better controlled. This isn't a permanent exclusion—once you achieve stable remission, you can reapply for assessment. Your safety always takes precedence over treatment speed.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
  3. Danese, S., Fiorino, G., & Peyrin-Biroulet, L. (2023). Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 21(6), 1400–1417. https://doi.org/10.1016/j.cgh.2023.02.013 [accessed 13 August 2026]
  4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Patients with ulcerative colitis or other inflammatory bowel disease should inform their prescriber and gastroenterologist before starting any weight loss medication. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can you take Mounjaro if you have ulcerative colitis?
Patients with well-controlled ulcerative colitis in stable remission may be considered for Mounjaro treatment, subject to individual UK prescriber assessment. Those with active flares or poorly controlled disease typically require IBD stabilisation first before weight loss medication can be safely initiated.
What is the mounjaro and ulcerative colitis timeline UK for starting treatment?
The timeline begins with a 2.5 mg weekly dose for four weeks, followed by gradual escalation every four weeks based on tolerability. Patients with ulcerative colitis require closer monitoring during weeks 1-12 to distinguish medication side effects from potential IBD flare symptoms.
Does Mounjaro make ulcerative colitis worse?
Mounjaro does not directly cause ulcerative colitis flares, but its gastrointestinal side effects (nausea, diarrhoea) may overlap with or mask IBD symptoms. Patients with active disease may find these effects more difficult to tolerate, which is why stable remission is typically required before starting treatment.
What are the warning signs of a UC flare whilst on Mounjaro?
Red flag symptoms include bloody diarrhoea, severe abdominal cramping that worsens over time, fever above 38°C, more than six bowel movements daily, or visible blood or mucus in stools. These require immediate medical review to determine if you're experiencing an IBD flare rather than normal medication side effects.
How long do Mounjaro side effects last with ulcerative colitis?
Normal GLP-1 side effects typically peak during weeks 2-6 after starting or increasing doses, then gradually improve over 4-6 weeks. If gastrointestinal symptoms persist beyond eight weeks or worsen rather than improve, this may indicate treatment intolerance or an IBD flare requiring prescriber review.
Should I tell my gastroenterologist I'm taking Mounjaro?
Yes, absolutely. Your gastroenterologist should be informed before starting Mounjaro so they can monitor your ulcerative colitis status and adjust your IBD treatment schedule if needed, as tirzepatide affects gastric emptying and may influence oral medication absorption timing.
Can Mounjaro help with weight gain from ulcerative colitis steroids?
Mounjaro may help address steroid-induced weight gain once your ulcerative colitis is in stable remission and you've tapered off high-dose corticosteroids. However, patients on active steroid treatment for IBD flares are typically not suitable candidates until their disease is controlled and steroid dose reduced.
What weight loss alternatives exist for active ulcerative colitis patients?
Patients with active ulcerative colitis may be better suited to non-GLP-1 options like Mysimba (which has less direct GI impact) or focusing on dietary management with an IBD-specialist dietitian until remission is achieved. Your UK prescriber will recommend the safest approach based on your current disease activity.
What is the Mounjaro and ulcerative colitis timeline in the UK?
Current research on Mounjaro and ulcerative colitis is still emerging, as tirzepatide is primarily licensed for type 2 diabetes and weight management. If you have ulcerative colitis and are considering Mounjaro, Cured Pharmacy's prescribers will review your full medical history to ensure suitability and safety before treatment.
Can I use Mounjaro if I have inflammatory bowel disease like ulcerative colitis?
Mounjaro may not be suitable for everyone with inflammatory bowel conditions, and a thorough assessment is essential. Cured Pharmacy's UK-registered clinicians will evaluate your ulcerative colitis status, current medications, and overall health during your online consultation to determine if Mounjaro is appropriate for you.
Does Mounjaro affect ulcerative colitis symptoms or flare-ups?
There is limited clinical data specifically linking Mounjaro to ulcerative colitis symptom changes, though GI side effects like nausea or diarrhoea may occur. If you experience worsening bowel symptoms while using Mounjaro from Cured Pharmacy, contact your prescriber immediately to discuss your treatment plan.
How do I get the cheapest Mounjaro price in the UK with pre-existing conditions?
Cured Pharmacy offers Mounjaro from £124.99 with £20 off using code Weightlossnew, even if you have pre-existing conditions like ulcerative colitis. Our prescribers conduct comprehensive health assessments to ensure safe, affordable access to Mounjaro tailored to your medical history.
Is Mounjaro cheaper online than through the NHS for ulcerative colitis patients?
Mounjaro is not currently available on the NHS for weight loss, so private prescriptions are required regardless of ulcerative colitis status. Cured Pharmacy provides competitive pricing from £124.99 with fast online consultations, making it a convenient and affordable option for eligible UK patients.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.